Company
Lumos Diagnostics Holdings Ltd
Headquarters: Melbourne, VIC, Australia
CEO: Dr. Robert P. Sambursky M.D.
Lumos Diagnostics Holdings Ltd Categories
Australia Healthcare Diagnostics & ResearchAustralia Healthcare Australia Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; ViraDx, a combined COVID/Influenza test for acute respiratory infections; and CoviDx, an antigen test for COVID-19. The company also engages in the contract research and development services specialized in the innovation, development, commercialization, and manufacturing of point-of-care diagnostic solutions for clinical and consumer applications. It offers its products through distributors primarily in the North American and European markets. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Lumos Diagnostics Holdings Ltd has the following listings and related stock indices.
Stock: ASX: LDX wb_incandescent
Stock: OTC: LDXHF wb_incandescent